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1. Introduction
Glioblastoma multiforme (GBM) is the most prevalent and lethal type of primary central
nervous system tumors with a medium survival of 10-12 months, even with aggressive sur‐
gery, radiation and advanced chemotherapy [1]. Poor prognosis of patients with GBM has
recently been connected with elevated expressions of a sphingosine kinase [2].
Although, GBM is an extremely lethal cancer, metastatic cancers to the brain from other or‐
gans are the most common intracranial tumors, out numbering GBM and other primary
brain tumors by at least 10-fold [3]. Lung, breast and melanoma are the 1, 2, 3 most common
cancers that metastasize to the brain [4]. The prognosis for these patients is worse than for
primary CNS malignancies – 3.7 vs.10-12 months for GBM [5].
Intracranial tumors, primary as well as metastatic, are increasing at an alarming rate since
many patients with excellent quality of life who appear to have ‘beaten the odds’ develop
metastatic disease to the brain after years of remission from breast and other cancers [3-6].
The development of CNS metastasis results in progressive physical and cognitive impair‐
ment and culminates in death within a few months of diagnosis.
In the US alone, the incidence of brain metastasis is expected to exceed 200,000 cases in 2012
– more than 20 times the incidence of primary high grade brain tumors. The median surviv‐
al time for metastatic cancer to the brain is 2-3 months and with aggressive therapy – maybe
4-12 months [6]!
Over the past 25 years, approximately 4-25 MM cancer patients have died with brain meta‐
stasis! These staggering facts strengthen a plea for developing new treatments for both pri‐
mary and secondary cancers of the brain.
There are many reasons so few drugs are available to treat CNS cancers. Classically pa‐
tients with brain metastasis have been excluded from clinical trials because of their poor
© 2013 Morgan; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
prognosis; the FDA has always had concerns regarding patient safety during Phase I trials
with unknown drugs that may cause CNS toxicity and finally once a new drug is identi‐
fied to have activity in non-CNS cancer involvement, few sponsors want to risk the poten‐
tial  hazards of  toxicity that could result  from treating patients with CNS involvement –
primary or  metastatic.  Thus,  there have been limited attempts to develop drugs for  pa‐
tients with brain metastasis, as well as primary brain tumors. The problem has been com‐
pounded  by  the  lack  of  attention  to  CNS  drug  distribution  and  penetration  of  brain
tumors, with reduction in toxicities.
Thus, there is a major need for the development of unique anticancer molecules that are able
to cross the blood brain barrier (BBB), initiate anticancer activity in the CNS tumors and are
non-neurotoxicity.
2. Landscape analysis of drugs available for brain tumors
• Temodar (temozolamide, TMZ (Schering-Plough,) is currently approved and marketed
by Schering-Plough for the treatment of high-grade glioblastoma multiforme and refrac‐
tory anaplastic astrocytoma in both in combination with radiation.
• Gliadel (BCNU wafer, Eisai) is an implantable wafer also used for the treatment of pri‐
mary brain tumors.
• Avastin (bevacizumab, Genentech/Roche) is an anti-angiogenic inhibitor that is being
combined with other agents that can penetrate the BBB. Combinations such as Avastin
plus Camptosar (irinotecan/CPT-11) +/- Temodar are in trials.
• Tarceva (erlotinib, OSI Pharmaceuticals), was granted FDA orphan drug designation in
August 2003 for patients with malignant gliomas, a recent study of Tarceva found 16% of
patients with malignant gliomas who were given Tarciva alone or in combination with
Temodar showed tumor shrinkage. The main side effect was an acne-like rash.
• Iressa (gefitinib, AstraZeneca) and has been approved for relapsing non-small cell lung
cancer. A recent phase II trial of Iressa in patients with relapsed glioblastoma resulted in
one of 52 patients achieving a partial response and 22 patients achieving stable disease.
Side effects were limited to rash and diarrhea.
• Zarnestra  (tipifarnib,  Johnson  &  Johnson  Pharmaceutical)  is  in  early  phase  trials  for
brain tumors.  The drug is also being studied in patients with leukemia and breast or
lung cancers.
• 81C6 is a tenascin radioactive monoclonal antibody that is injected into a cavity created
by the neurosurgeon after removal of the tumor. The antibodies deliver radiation to kill
the tumor cells with less radiation to normal brain tissue than conventional radiotherapy.
The product is under development at Duke Comprehensive Cancer Center.
• BMS-247550 (Bristol Myers Squibb) is in Phase II/III @ Memorial Sloan-Kettering.
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• Ipilimumab (yervoy, Bristol Myers Squibb) a monoclonal antibody to CTLA-4 has activi‐
ty in melanoma with improved PFS.
• Vemurafenib (zelboraf, Genentech) is a BRAF inhibitor approved to treat melanoma,
however, CNS mets were excluded in the trials, so the drug is being checked formally
now.
• Cisplatin + etoposide, capecitabine (Xeloda), etc. – TTP/PFS - 3 mos max
• Dabrafenib and trametinib have delayed melanoma progression (GlaxoSmithKline)
• And others ……………… [7-9]
3. A new approach to new novel agents for – 1o and 2o brain tumors
The current trend to develop ‘personalized therapy’ based on the presence of specific pheno‐
typic or genotypic pathways is an improved approach over the structure activity relation‐
ships (SAR) of the 20th century medicinal chemists [10]. However, the management of
unresectable brain tumors has not improved. There is still a deficit in drugs that cross the
blood brain barrier (BBB), are not recycled out of the brain, are effective anticancer agents in
the CNS and do not require hepatic activation. Most of the 21st century ‘personalized medicine’
drugs are large molecules that are given with other drugs and are ionizable chemicals that
cannot penetrate the BBB and/or recycled out of the brain.
A suggested platform for new novel agents – that might be effective therapies for brain tu‐
mors comes from the earlier 20th century literature that focused on – ‘the energy of cancer cells
vs. normal cells’ [11-13].
Brain tumor biochemistry began in 1930 with Warburg's publication - The Metabolism of Tu‐
mors [12]. The fundamental finding of this publication was that embryonic and tumor tissues
have in common a high glycolytic metabolism even under aerobic conditions; in contrast to
most normal tissue where oxidative metabolism predominates. The oxidative metabolism in
cells is generally 16 x more economical in respect to energy than the glycolytic pathway. The
Embden-Meyerhof glycolytic pathway is phylogenetically the more primitive form [12]. In
rapidly growing de-differentiated tissue, this pathway prevails over oxidative metabolism.
These concepts are of interest because the energy for a healthy cell is generated from glucose
where 36 ATP molecules are produced from 1 glucose molecule. Hydrolysis of ATP results
in a free energy change of ~ -16,000 cal/ATP molecule, depending on the conditions.
Classically cancer cells generate 2 ATP/1 glucose molecule vs. 36 ATP/1 glucose molecule
(for healthy normal cells) – with the end product of pyruvate, rather than CO2 and water
as occurs in healthy cells [12]. Otto Warburg explained the latter as a result of the cancer
cell’s energy-transfer conversion to aerobic glycolysis, a major shift in energy available for
cellular work [12].
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Albert Szent-Gyorgyi referred to the energy differences of cancer cells vs. normal cells as –
the alpha (α) state with ↑∆S and ↓∆F vs. the beta state (β), with ↓∆S and ↑∆F), resp. [13].
The α state is the ground state of life! The most stable state of any system is with minimum
∆F and maximum ∆S. If the cellular organization becomes unstable, cells will return to an α
state and remain there. The more complete the return – the harder it will be to reverse.
The β state is where there is a high degree of differentiation and potential for release of F if
the cells react and initiate differentiation. Here the energy present allow cellular regulation
and multicellular organisms replication; not a mass of undifferentiated cells – cancer.
[Where, S = entropy or potential (stored capacity) for a reaction to occur and F (free energy),
a state of function depending only on the initial and final states of a system [14].
The importance of ΔF is that the value immediately provides quantitative information about
the potential ability of a substance to undergo a chemical or physical transformation. A reac‐
tion may proceed spontaneously without external energy only if the ΔF is negative (energy
dissipated) [14]. Chemical thermodynamics tells us that “F needs to be a released in order for the
cell to be productive and do work, not just replicate with a low productive reactivity” [13].
We should view entropy as an index of a condition or character. It is an index of the capacity
for spontaneous changes. By historical accident, the index was actually defined so that it
increased as the capacity of an isolated system for spontaneous change decreased.
Hence, entropy is an index of exhaustion. The more a system has lost its capacity for spontane‐
ous change, the greater is the entropy [14].
Yes, cancer cells represent a primitive, high random energy, low functional state with unbri‐
dled proliferation [13]. Cancer cells are not sick or weak, their vitality, as a wild type, may
be even higher than that of a normal cell.
The cancer cell is unable to rebuild its beta state after it has completed its division and has to
persist in the proliferative alpha state until death. In itself, the proliferative state would not
be pathological – it is only its timing and irreversibility, which makes it so. It is not pathologi‐
cal to be an infant, but it is pathological to be one and remain so x 50 years!
Is cancer an outward manifestation resulting from depletion in cellular free energy within
cells and increased entropy?
Although oxygen is considered essential for life, sulfur (S) and phosphorus (P) are the most
common biological selections for energy transfer. The latter two elements are members of
the Third Period of the Periodic Table and are capable of accepting an additional pair of
electrons into unoccupied 3d orbitals. This phenomenon is characteristic of the elements of
the Third Period, which possess d, in addition to s and p orbitals, and thus have a place to
hold electrons beyond the normal outer-shell octet. Molecules that possess P or S can store
electrons (energy) and then release the energy during the transfer of shared electrons to oth‐
er electron deficient molecules [15].
ATP (Fig. 1) is a unique example of how a 3rd Period element - ‘P’ participates in a key natu‐
ral energy-rich compound, which upon hydrolysis generates ~ 8 kcal/mole upon hydrolysis
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with a +ΔF. When hydrolyzed in the presence of suitable transformers (transducing sys‐
tems), the energy liberated may be used for cellular or tissue processes – cellular metabo‐
lism, nerve conduction, cell membrane transport, etc.
Figure 1. Adenosine triphosphate (ATP)
Energy rich phosphates usually possess either a second phosphoryl group or a resonating
organic radical capable of entering into conjugation with the mobile electrons. This type of
molecule usually contains a chain of at least three adjacent atoms, all bearing a net positive
charge (deficient in π electrons), the chain sometimes extends over a five or even six atoms
[Fig. 2], [16].
Figure 2. Examples of 3-atom high-energy moieties
Many of the small molecules used as anti-CNS cancer agents also possess 3-atom high ener‐
gy moieties (in red) [3]
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Figure 3. Small Molecules that are used to treat CNS cancer
Where: DM-PEN carbonate, 1 is a carbonate analog of 4-demethyl penclomedine; PRZ, 2 is
dacarbazine; Temodar®, 3 is temozolamide (TMZ); BCNU, 4 is bis-(chloroethyl)nitrosourea;
HOOI, 5 is 4-hydroperoxyifosfamide; Clomesone, 6 is a chloroethylating agent similar to
BCNU – alkylates guanine-O6 [17].
Compounds can be classified as “energy-rich” or “energy-poor” based on their ΔF. Energy
poor compounds do not possess more than two adjacent atoms bearing a positive charge
and poorly absorbed by the CNS.
Thus, the design of “high-energy molecules” that are lipophilic, energetic and absorbed into
a low free energy (ΔF) and high entropy (ΔS) cancer environment are timely. The latter is a
unique therapeutic target – the result of inefficient energy of cancer cells [14].
Life is controlled by the transfer of energy. All living systems obey the 1st law of thermo‐
dynamics – which states that the sum of all  energies in an isolated system remains con‐
stant. Energy may be converted into another form but the quantity can be neither created
nor destroyed [18].
A question to be answered – are high energy compounds really attracted to low energy
highly utilized regions in the body?
4. Polyhalogenated pyridyl carbonates [16, 19-21]
The polyhalogenated pyridyl carbonates are neutral molecules that when coupled with lip‐
ids via high energy linkers – carbonates, phosphates, etc., fulfill the above requirements for
novel high energy anticancer agents that could be attracted to and accumulate in CNS can‐
cer tissue [16, 19-21]. The carbonate moiety like phosphate has the properties (resonance) of
the high energy 3-atom moieties described in Fig. 3.
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DEKK-TEC has designed a series of polychlorinated pyridyl carbonates (with 1 as a tem‐
plate, Fig. 3) that are linked with lipids and lipophilic moieties to promote CNS penetration
[19]. DM-CHOC-PEN (4-demethyl-4-cholesteryloxycarbonylpenclomedine) is the most ac‐
tive and stable member of a large series of carbonates with improved activity vs. intracrani‐
ally (IC) implanted human xenograft models – U251 and D54 glioblastoma and MX-1 breast
cancer [Table 1] [19].
DM-CHOC-PEN is a unique molecule with several functional moieties that enable it to in‐
hibit cancer replication. The structure contains the following moieties of interest:
Figure 4. Lipophilic cholesterol link - blue. Carbonate linker that contains the properties seen in the elements of 2nd
and 3rd period elements with higher energz storage potential - green. A pyridinium ring system that can transfer elec‐
trons via resonance into intermediary metabolism, ATP synthesis and substrate for the ABC cassette transport / red
The importance of the carbonate moiety is its internal energy and ability to transfer electrons
through multiple structures (resonance) (see Fig. 5):
Figure 5. Mesomeric forms of the carbonate; where R = pyridyl group & R'=cholesterol
The additional oxygen in the carbonates [Fig. 5, lower structures] stabilizes the moiety and
allows for distribution of charge through resonance (Fig. 5). This chemical property exists in
the phosphates and other oxides of the 3rd period elements [see below] [15].
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Scheme 1.
In contrast, esters lack the degree of resonance/electron distribution [Fig. 5, upper structures].
As indicated in Fig. 5, a carbonate is not isosteric with an acyl or ester group nor is it a direct
extension of an ester group. The carbonate group is unique and when combined with cho‐
lesterol its CNS penetration properties are enhanced [Table 1] [16].
DM-CHOC-PEN BCNU TMZ
Tumor *Dose %ILS %LTS +Dose %ILS %LTS #Dos %ILS %LTS
U251
Glioblasto
ma
135 +54 +20(1/5CR) 9 52
+20(1/5
CR) 120 +54
+20(1/5
CR)
D54
Glioblasto
ma
200 +3 +20(1/5CR) NA NA NA NA NA NA
MX-1
Breast
Cancer
50
100
+20
Toxic 17(1/6 CR) 60 12 0/5 NA NA NA
Table 1. Activity of DM-CHOC-PEN vs. Intracerebrally Implanted Xenograft Tumors in Mice
Implant: 106 cells IC; Treatment Route: Intraperitoneal (- 5 days post IC implant); Schedule:
*IV q1d x 5d; +IV q1d x 3d; #po 1d x 5d; Species: Athymic NCr/nu mice – female, Charles
River; Dose: mg/kg; %ILS = % increased life span; %LTS = long term survival; all studies
were terminated at 54 days
Based on the preclinical antitumor activities in Table 1, DM-CHOC-PEN produced a moder‐
ate increase in life span (% ILS); however it was comparable to that seen with BCNU and
TMZ. DM-CHOC-PEN did yield long-term survivors that were healthy with no weight loss.
Even the highly resistant IC implanted D54 glioma was sensitive to DM-CHOC-PEN. The
drug has minimal toxicity and has encouraging potential [16, 19, 21].
An in  vivo  activation  mechanism scheme is  shown in  Fig.  6,  where  DM-CHOC-PEN is
proposed to  be  acting  as  a  non-classical  alkylating  agent.  The  scheme describes  a  dual
carbonium ion - DNA cross-linking mechanism (in a G-X-C sequence) with tumor DNA
in  the  major  groove  via  N7-  guanine  [20].  A  bi-molecular  coupled  product  (via  the  tri‐
chloromethylene group) has been identified as the major microsomal metabolite of  PEN
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[20].  The  trichloromethylene  group  is  required,  since  the  dichloromethylene  analog  of
PEN is  not active [does not react  with 4-(p-nitrobenzyl)  pyridine (NBP] (Struck,  person‐
nel communication).
Figure 6. Proposed mechanism of action of 4 - demethyl - 4 - cholesterolyl - penclomedine (DM - CHOC - PEN)
Mice with IC growing U251 gliomas were treated with DM-CHOC-PEN, 135 mg/kg daily x
5-days and after 3-days the animals were sacrificed and the brains with tumors removed.
The tumors were easily separated from the normal brain tissue. Each was homogenized in
phosphate buffer, extracted with dichloromethane, and evaporated to dryness. The residues
were assayed by HPLC and DM-CHOC-PEN, a guanine-N7-CCl2-adduct with DM-CHOC-
PEN involving the –CCl3 moiety and the DM-CHCO-PEN dimer-Cl2C-CCl2- were identified
in the glioma tissue [16]. Neither DM-CHOC-PEN nor metabolites could be identified in the
normal brain tissue.
Thus, DM-CHOC-PEN alkylates DNA with adducts at guanine-N7 that could be quantitated
in tumor tissue. The above MOA is in contrast to TMZ, BCNU and others, which alkylate
guanine-O6 [22].
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The polyhalogenated pyridyl carbonates are unique structures that cross the BBB, accumu‐
late in CNS tumor tissue, not normal brain tissue and are not recycled out of the CNS are
cytotoxic vs. intracranially (IC) implanted human tumor xenografts in mouse models; fulfill‐
ing all of the criteria of the preceding paragraphs [23].
The combinations of responses in mouse xenograft tumor models, and a lack of neurotoxici‐
ty in rat and dog biopsychology studies, have allowed a Phase I trial to be conducted with
DM- CHOC-PEN in patients with advanced cancer, including CNS involvement - IND
68,876 [24].
DEKK-TEC and its clinical investigators have satisfied the FDA that they are capable of
treating patients with Phase I drugs and diagnosing physical and mental/cognitive altera‐
tions that may be associated with CNS tumor growth vs. toxicity secondary to drugs.
5. Phase I clinical trial with a high energy drug – DM-CHOC-PEN
Weiner, Ware, Friedlander, et al. reported preliminary data from a Phase I trial involving 18-
patients treated with DM-CHOC-PEN in single IV doses of 39-87.5 mg/m2 once every 21-
days [25]. Six [6] patients had either CNS or spinal nervous system (SNS) involvement. Most
patients had multiple treatments. The longest survivor (a sarcoma w/ SNS involvement) is
19+ months with NED [who also received doxorubicin at a later time] [25].
Support for DM-CHOC-PEN crossing the blood brain barrier in humans is provided from
the above trial with reported observations for – GBM, CNS melanoma and breast cancer
(BC) having PFS 4-13 mos., objective reductions in tumor sizes and no CNS toxicity.
One patient with pelvic sarcoma spread to the spinal cord required debulking surgery 21-
days post treatment with DM-CHOC-PEN (39 mg/m2). Tumor tissue was removed, assayed
and DM-CHOC-PEN was quantitated in the spinal sarcoma tissue – 92 ng/g of tumor [25].
The only SLTs noted to date are hyperbilirubinemia in 2-patients with liver metastasis; pa‐
tients with no liver pathology have not demonstrated SLTs. CNS toxicity has not been noted
in any of the patients. Overall, the drug was reported as being tolerated very well [25].
6. CNS melanoma
Melanoma is the third most frequent cancer to metastasize to the brain. It is anticipated that
there will be ~ 20,000 new cases of CNS stage melanoma diagnosed in 2012 [9]. Enrollment
of these patients with CNS melanoma would be critical to appreciating the activity of the
demethylpenclomedine carbonates in this stage of disease [9, 26]. Two of the patients enrol‐
led and treated in the DM-CHOC-PEN Phase I trial had CNS melanoma; one patient had
significant shrinkage of CNS lesions, the other stable (NC) disease [25].
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To test the potential sensitivity of DM-CHOC-PEN as therapy for melanoma, the B-16
mouse melanoma was selected as a screening model and treated with DM-CHOC-PEN in
vitro and in vivo [28].
7. Experimental methods
In Vitro – B-16 mouse melanoma cells [obtained from ATCC, Menassas, VA] were assayed
in culture wells (104/mL) using a complete RPMI media containing 10% FBS with pen/strep
and maintaining cells @ 36o C in a CO2 incubator. Drugs (in 1 mL volumes; in conc. - 0.1-5
µg/mL) were added to the cells in a growth phase and removed after 8-12 h; cultures were
washed with fresh medium. For florescent studies - cells in growth phase were incubated
with dichlorofluorescein diacetate (DCFDA, 3 µg/mL RPMI) x 1-hr, washed and DM-
CHOC-PEN added (1-5 µg/mL); incubation continued for an additional 5-hour. Cells were
washed with fresh complete media and monitored with fluorescent microscopy. For the lat‐
ter – RPMI without phenol red was used.
In Vivo – B-16 mouse melanoma cells (106) were implanted SC into the flank of adult female
C57BL mice (age – 7-9 weeks, Harlan Labs.) and treatments with DM-CHOC-PEN, HOOI,
and other drugs began were initiated when lesions were palpable - 3-5 days post implant.
Drugs – were dissolved in saline or in a soybean oil/egg yolk lecithin emulsion (2 mg/mL)
and administer by IP injection. HOOI was administered as the L-lysine salt [27].
Results – B-16 cells were incubated with DM-CHOC-PEN and after ~ 6-8 hours became
heavily melanotic, lost adherence and floated to the top of the wells. Isolation of the floating
heavily pigmented melanotic cells that formed (Fig. 7b), followed by washing, extraction
with dichloromethane, and HPLC assays revealed that the cells contained DM-CHOC-PEN
in concentrations of 0.003-0.09 µg/mL of packed B-16 cells. Attached amelanotic cells con‐
tained 0-20 ng/mL of DM-CHOC-PEN (significant) [28].
 
 
 
 
 
 
(a) (b) 
Figure 7. a) B-16 melanoma cells – untreated; b) After treatment with DM-CHOC-PEN
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In comparison with other agents – DM-CHOC-PEN had an IC50  of 0.4 µg/mL and TMZ,
BCNU, DOX and actinomycin D (Act D), HOOI – 0.5-0.9 µg/mL; cis-platinum (cis-platin)
–  1.5  µg/mL resulted in  IC50  cell  death @ 36 hour post-intial  exposure.  With the excep‐
tion  of  DM-CHOC-PEN,  all  treated  cells  died  with  ghosts  remaining;  excesive  melanin
formation only occurred with DM-CHOC-PEN; the terminal pathways were quite differ‐
ent for the other drugs.
Drug IC50 (µg/mL)
DM-CHOC-PEN 0.4 +/- 0.01
Actinomycin D 0.5 +/- 0.02
BCNU 0.9 +/- 0.1
cis-Platin 1.5 +/- 0.1
DOX 0.7 +/- 0.1
TMZ "/>3.0
HOOI 0.8 +/- 0.2
Table 2. Drugs Responses vs. B-16 Melanoma (IC50)
Figure 8. a)B-16 cells + DCF-DA; b)B-26 cells plus DM-CHOC-PEN + DCF-DA
Viewed with florescent microscopy – green florescent cells are generating ROS and the DCF
is florescent.
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Melanoma cell  death due to DM-CHOC-PEN could be a result of increased intracellular
melanin, as well as DNA alkylation. Addition of DCF-DA (dichlorofluorescein diacetate)
to the culture medium (10 µg/mL) documented the formation of  radical  oxygen species
(ROS) in the DM- CHOC-PEN treated cultures; green labeled cells (Fig. 8b). ROS release
was documented with DCF, which is due to the hydrolysis and oxidized of DCF-DA by
ROS with the release of fluorescent DCF. The generation of ROS was not observed with
B-16 melanoma cells treated with cis-platin or actinomycin D and cultured under similar
conditions.  There  is  some back ground florescence and secondary to  melanin-associated
ROS formation [16].
In Vivo Studies – Adult female C57BL mice in groups of 5-6 mice with palpable SC nodules
were dosed IP daily (175 or 200 mg/kg) for 5-days with DM-CHOC-PEN and monitored dai‐
ly until death (Fig. 9a).
Mice treated with DM-CHOC-PEN (200 mg/kg/d x 5 days, IP) alone demonstrated an ILS of
142% (Fig. 9a). No drug related toxicity was noted – weight gain occurred until tumor
growth was obvious.
Figure 9. a)DM-CHOC-PEN treated; b)Cis-platin treated
Cis-platin was used as a drug control and administered (IP) once weekly x 3 (Fig. 9b); ani‐
mals did not tolerate 3- or 5-day dosing schedules [28, 29]. Although active in vitro, cis-platin
does not improve in vivo survival – as seen in Fig. 9b, although it is used in many melanoma
clinical protocols [3].
Tumor histology of the DM-CHOC-PEN treated B-16 melanomas are reviewed in Fig. 10. On
the left (a) is the saline control and right (b) the DM-CHOC-PEN treated – 200 mg/kg IP dai‐
ly x 5 days. Note - the melanin deposits in the cells with vacuoles, similar to what was seen
in culture [29].
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(a) (b) 
Figure 11. a)Histology of saline controls; b)Histology of DM-CHOC-PEN treated
Tumor tissue from the above DM-CHOC-PEN treated mice were assayed per cytoflorimetry
using a BD FAC Scanner.
 
 
 
 
 
 
 
(a) 
(b) 
Figure 12. a) Mice bearing SC nodules – control animals. b) Mice bearing SC nodules dosed - 200 mg/kg; days 1-5 and
sacrificed 3-days after the last treatment.
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There were less viable cells available in the treated animals. DM-CHOC-PEN reduced the
cellular concentration of the tumors and the cells accumulated in G1 phase, with an inhibi‐
tion in S-phase concentration of cells (Fig. 11b). Thus, more support for DM-CHOCPEN’s
potential use in melanoma. Unfortunately, there was a significant amount of debris present.
Discussion – Mice bearing B-16 melanoma, tolerated DM-CHOC-PEN well when adminis‐
tered IP daily x 5 days or days 1 & 5 with improved overall survival (OAS) for both sched‐
ules; the former was the superior.
Histological examinations of the melanoma tissue from animals that had been treated with
DM-CHOC-PEN revealed tumor cells encompassed in extracellular melanin, very similar to
what was seen in tissue culture (Fig. 7b). DM-CHOC-PEN was extracted in up to 92 ng/g
tissue quantities from the melanoma tissue removed in Fig. 11b [16].
DM-CHOC-PEN is a pseudo-alkylator that binds to DNA’s guanine-N7 via the trichloro‐
methyl moiety → dichloromethylene carbonium ion and can form DNA-guanine adducts
and cell death [Fig. 6] [9]. However, the current observations in a melanoma model support
DM-CHOC-PEN’s additional ability to disrupt cellular metabolism with death via autooxi‐
dation of DOPA to melanin and superoxide formation – an additional MOA for considera‐
tion – Fig. 12 [28, 29].
Electronic modeling studies support DM-CHOC-PEN’s ability to act as a pyridinium co-fac‐
tor oxidized by the pyridine nucleotides (NAD, etc.) with red-ox transfer of electrons from
3,4-dihydroxyphenylalanine (DOPA) to the mitochondria and cytochrome C/cytochrome ox‐
idase transport system (Fig. 13). This result is the formation of 5, 6-indolequinone and mela‐
nin with a trail of electrons that can enter the mitochondrion intermediary pool resulting in
all the same type of lethal changes seen with electron beam therapy for cancer [30, 31].
The ‘melanin balls’ that were seen in vitro are spheres of extracellular melanin polymer en‐
capsulating colonies of melanoma cells that could induce a hostile microenvironment
through ROS formation with death via oxidative stress and apoptosis (Figs. 10) [30]. Clus‐
ters of melanin laden cells contained significantly elevated concentrations of DM-CHOC-
PEN, as compared to the amelanotic variant; a possible storage site for the drug [31]. The
initial DOPA → DOPA quinone transformation is catalyzed by tyrosinase (DOPA oxidase)
intracellular [32-35]. However, the red-ox potential for DM-CHOC-PEN is sufficient to cata‐
lyze the conversion with excess melanin formation per the Rapier Scheme below [32].
Both malignant and benign melanocytes generate melanin pigment via the sequence of
chemical reactions as depicted in the classical Rapier Scheme in Fig.12 [32].
Melanin is far from being an end-product of oxidation [34-37]. At a glance the existence of
energy bands are obvious from the highly conjugated heterocyclic indole quinone structure
for melanin (Fig. 12). The hypothesis has been proposed that non-localized empty molecular
orbitals are associated with the copolymer chain of the indole quinoid units and that the
melanin polymer acts as a one-dimensional semi-conductor/trap with bound protons pro‐
ducing electron traps in the system [36].
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Thus, melanin is a polymer of indole-5, 6-quinone which is highly electrophilic due to its
conjugated structure and capable of attracting, storing and/or transferring electrons as elec‐
trical energy [30, 31, 34]. DM-CHOC-PEN treatment induced ROS formation via the melanin
system resulting in cancer cell death – an end point.
Figure 13. Interaction of DM-CHOC-PEN with Rapier melanin cell cycle and mitochondrion [32]
Melanin is potentially a storage deposit of electrons and/or for electron-rich molecules (re‐
ported by our group years ago) [31]. Due to the high redox potential between DOPA and
DOPA quinone, +0.37v, a possible yield of -19.8 kcal/mole occurs upon the oxidation of 1
mole DOPA. A total of 12 e- are generated per mole of DOPA oxidized to indole quinone
which polymerize to melanin [Fig. 13 [31]. A field of melanin encompassing a colony of can‐
cer cells could generate a hostile electrical microenvironment and inhibit cellular metabo‐
lism and replication [33].
Melanoma cells are a classical representation of cancer cells with a resting low free energy
(ΔF) and high entropy (ΔS) – the alpha state [14]. The interactions of DM-CHOC-PEN and
DOPA induced the formation of melanin and ROS which resulted in an increased envi‐
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ronmental ΔF and a decrease in ΔS; a new resting high energy state – the beta state.  The
cells that are contained in the melanin balls are in a beta state - undergo apoptosis and die
[28, 30, 31].
Thus, DM-CHOC-PEN is a new drug entity that crosses the BBB and couples two new tar‐
gets – the melanin cycle and superoxide formation with apoptosis plus DNA guanine – N7
adducts. DM-CHOC-PEN is a potential triple treat for CNS melanoma, the 3rd most common
cancer that spreads to the CNS.
8. A 2nd High energy drug
Another high energy drug, 4-hydroperoxyifosfamide (HOOI) [Fig. 3, 14] and is a pre-activat‐
ed form of ifosfamide (IFOS) which possesses the criteria for discussion [Fig. 14]. HOOI also
contains a 3rd Period atom – ‘P’; thus it has two centers of high energy – Fig 3, 14.
O
P
N O
CH2CH2Cl
NHCH2CH2Cl
R
HO
P
HN O
CH2CH2Cl
NHCH2CH2Cl
Where: R = H; Ifosfamide (IFOS)
R = OH; 4-Hydroxyifosfamide (HO-IFOS)
R = OOH; 4-Hydroperoxyifosfamide (HOOI)
Isophosphoramide
Mustard (IPM)
Figure 14. Ifosfamide and analogs
IFOS is a well-known anticancer agent that requires hepatic activation to 4-HO-IFOS which
spontaneously undergoes hydrolysis with ring opening resulting in isophosphoramide mus‐
tard (IPM) [Fig. 14], the latter is the active cytotoxic form of IFOS [37-39]. As part of the IFOS
activation process, hepatic metabolic dechloroethylation releases chloroacetaldehyde, which
has been proposed to be the major cause of IFOS associated neurotoxicity [40]. Acrolein is
also released and has been implicated in dose limiting toxicities - hemorrhagic cystitis and 2o
tumor promotion [41-45].
In contrast, HOOI does not require hepatic microsomal activation, crosses the BBB and is
readily absorbed by cancer cells where it releases IPM in situ [46, 47]. The former does not
generate chloroacetaldehyde (neurotoxic) during its conversion to IPM, as does IFOS. Nei‐
ther hemorrhagic cystitis nor renal toxicity has been observed with HOOI in animal toxicol‐
ogy models. Pulmonary damage that could occur with peroxides – pulmonary air emboli
was not observed in the dog HOOI study [46]. Hematological toxicity (bone marrow deple‐
tion) was the dose limiting toxicity in the dog study [47].
The potential therapeutic usefulness of HOOI is supported by in vivo activity in human tu‐
mor xenografts and cyclophosphamide (CPA)-resistant murine tumor models plus reduced
toxicities.
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In vivo in comparison to CPA and IFOS in rodent and dog species [Table 3] [47], a potential‐
ly improved safety profile is anticipated – with reduced systemic formation of acrolein and
the absence of chloroacetaldehyde during the conversion of HOOI to IPM – in situ [47].
Drug Dose(mg/kg/day) No of Mice
MX-1*
T- C (Days)
ZR-75-1*
T- C (Days)
U251
(%ILS)**
P388/CPA (%
ILS)**
HOOI 90(<LD10)
10 >28.8 9(33% LTS) >46.1 (83% CR) +54 (1/5 CR) +209
+
DM-CHOC-PEN 135 10
>54 days
(20% LTS)
[Dose - 50]
NA +54 (1/5 CR) NA
IFOS 40(MTD)++ 10 8.6 (7% LTS) >43.8 (17% CR) 50 (0/5 CR) 42
IPM 40(MTD)++ 10 2.1 NA NA +85
BCNU 9-15 (MTD) 5 12% LTS; 0 CR NA +52 (1/5 CR) NA
TMZ 120 mg(MTD) 5 NA NA +54 (1/5 CR) NA
Dose – qd x 5d (IP) – except TMZ – PO Q4D x 3; *human breast cancer – SC implanted, **human glioblastoma – IC
implanted; ***CPA (cyclophosphamide) – resistant murine leukemia. For MX-1 – T-C (days) = difference in median
times post implant for tumors of treated groups to attain an evaluation size compared to median of control group; +6-
log cell kill; ++>40 mg/kg was too toxic; ***% ILS (increased length of survival – study terminated @ 54 days.
Table 3. Human Xenografts and Murine Tumors Growing in Mouse Models
HOOI possesses two [2] 3-high energy atom chains, thus the drug more than fits the criteria
proposed earlier in this chapter (3). In addition, HOOI does not require activation by the liv‐
er and spontaneously undergoes conversion to IPM and cross-links with nuclear DNA via
major groove alkylation – N7-guanine, forming G-X-C adducts [39].
Of significance is that HOOI was curative (54% LTS, with 20% CR) vs. the human U251 glio‐
blastoma implanted IC as well as the MX-1 breast cancer IC model (Table 3) [47]. It should
also be noted that BCNU – the gold standard for years in the treatment of gliomas produced
no CRs and TMZ the current standard produced identical responses to HOOI.
Like DM-CHOC-PEN, HOOI accumulates in U-251 glioma tissue in 50 ng/g tissue content
when the drug is administered IP to animals bearing IC implanted tumors [47]. No CNS/
behavioral alterations or toxicity have been noted for HOOI [48].
Unlike ifosfamide (IFOS), HOOI is more lipophilic, activated in situ, with less extracellular
acrolein, no chloroacetaldehyde released and no IFOS associated CNS or GU toxicity [48]. In
dogs the principal toxicity with HOOI was bone marrow suppression that reversed with
time [47, 48].
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An early study reported that SK-MEL-31 human melanoma cells were sensitive to HOOI,
which prompted the comparison of the drug with DM-CHOC-PEN in the B-16 melanoma
model [47].
In 2012, the incidence of new cases of melanoma in the US alone is estimated at 76,250, an
increase of ~ 20% during the past 10 years [9]. Of these cases, ~ 25% will metastasize to the
CNS; thus our interest in the drug [26].
Fig. 15 describes the impact on survival of B-16 mouse melanoma when HOOI is adminis‐
tered alone and with DM-CHOC-PEN [49].
DM-CHOC-PEN (200 mg/kg/d) was injected IP daily x 5-days followed by HOOI (90 mg/m2)
IP daily x 3 days (Day 6-8). The latter is a more classical mustard type agent with activity in
the G1 phase, as compared to DM-CHOC-PEN, which inhibited cell replication at the S
phase – Fig. 12b [49].
The %LTS for the 2-drug combination was 173% vs. HOOI alone - 78%; for DM-CHOC-PEN
alone - 142% (see Fig. 14).
No drug related toxicity was noted – weight gain continued until tumor growth was a burden
and animals sacrificed. The use of 5-day dosing for HOOI was toxic and not considered [48].
Combination of the two -‘high energy’ agents selected for discussion as binary therapy has po‐
tential. It will be a while before these 2-drugs are administered together; however, other binary
selections that incorporate DM-CHOC-PEN are in the planning stage for Phase II trials.
Figure 15. DM-CHOC-PEN plus HOOI in the Treatment of B-16 Mouse Melanoma
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9. Conclusion
Melanoma cells, as seen in Fig. 7a represent classical cancer cells with a resting low free en‐
ergy (ΔF) and high entropy (ΔS) – the alpha state [14]. The interaction of DM-CHOC-PEN
and DOPA induced the formation of melanin – a high energy component/storage that re‐
sulted in an increase in environmental ΔF and a decrease in ΔS; a new resting high energy
state – the beta state [14]. Cells that are encompassed in the ‘melanin balls’ (Fig. 7b) were con‐
verted to a well differentiated state and die. The addition of HOOI to DM-CHOC-PEN in‐
hibited those cells that reversed to the alpha state – survive and continue to replicate. Thus,
the binary combination improved %LTS vs. either drug alone; supporting the in vitro obser‐
vations.
Although, only two patients with CNS melanoma have been treated with DM-CHOC-PEN
in the Phase I trial, the report that one patient did demonstrate an interval response and one
patent had a no change response, both with no neurotoxicity is encouragement for the po‐
tential use of the drug in the treatment of CNS melanoma [25]. HOOI has not been used in
clinical trials as yet.
There are many novel drugs that fall in to the ‘high-energy’ category that should be evaluat‐
ed or re-visited. In particular – clomesone [Fig. 3], a drug developed at Southern Research
Institute, US had potential in animal studies, but produced hematological toxicity in Phase I
trials and discontinued from studies [17, 50]. The drug has novel chloroethylating properties
and like BCNU forms adducts with DNA guanine-O6 [50]. In addition, the drug contains
two - S - atoms which are a 3rd Period element and able to expand its 3d orbital – a real
‘high-energy’ molecule. However, only one of the latter groups has the ability to resonant
with energy storage.
With the two sets of 3-atom chain as a point of interest (Fig. 3, 6), clomesone should be revis‐
ited with dose modifications; it has potential [52].
In summary, three ‘high energy’ drugs have been reviewed as support that a novel ap‐
proach to the treatment of CNS malignancies could be through the inefficient energy system
of brain tumors [11, 12]. Anticancer agents that have the appropriate structure, can penetrate
the CNS, not be recycled out and inhibit cancer growth.
Over all, DM-CHOC-PEN has been well tolerated in Phase I studies with advanced –breast
cancer, sarcoma, glioblastoma multiforme, melanoma, pancreas, esophageal, non-small cell
lung cancer colorectal cancer and cervical cancer and will obviously enter Phase II trials
alone or as binary therapy [25].
Furthermore, HOOI is being readied for Phase I clinical trials and the results should be
equally interesting.
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